Drug Trial Radar · NCT07704099
Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Sep 25, 2026
Primary completion
Aug 26, 2028
Study completion Sep 23, 2028
Sponsor
- Lead sponsor
- Keros Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KER-065 administered to adult and pediatric ambulatory and nonambulatory male participants with Duchenne Muscular Dystrophy (DMD) on stable background therapy.
Conditions
- Duchenne Muscular Dystrophy
Interventions
KER-065Drug
KER-065 will be administered subcutaneously (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs and serious adverse events (SAEs)Time frame: Up to approximately 14 months
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
LTD TIM - Tbilisi Institute of Medicine
Tbilisi, Georgia · Not yet recruiting
Institute of Neurology and Neuropsychology LTD
Tbilisi, Georgia · Not yet recruiting
Optimal Clinical Trials
Auckland, North Island, New Zealand · Recruiting
NZCR-Christchurch
Christchurch, South Island, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.